menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Shyndec Pharmaceutical","sponsor":"Shanghai Shyndec Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Terconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Shanghai Shyndec Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Shanghai Shyndec Pharmaceutical \/ Shanghai Shyndec Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Shyndec Pharmaceutical \/ Shanghai Shyndec Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Shyndec Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shanghai Shyndec Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Shyndec Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Shyndec Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Shyndec Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nifedipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shanghai Shyndec Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Shyndec Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Shyndec Pharmaceutical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Shyndec Pharmaceutical

    Menu

    Shanghai Shyndec Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nifedipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Ce...

                            Details : Xin Ran (Nifedipine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Xin Ran

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 06, 2015

                            Lead Product(s) : Nifedipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Terconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : Peking University Shenzhen Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

                            Details : Terconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Candidiasis, Vulvovaginal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2014

                            Lead Product(s) : Terconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : Peking University Shenzhen Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shanghai Shyndec Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nifedipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hyperten...

                            Details : Xin Ran (Nifedipine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Essential Hypertension.

                            Product Name : Xin Ran

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2014

                            Lead Product(s) : Nifedipine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth